Concepedia

Robert Croop

RC

Statistics

Publications

41

Citations

2.8K

H-Index

22

Active since

1995

Affiliations

Biohaven Pharmaceuticals (United States)(Current)

Albert Einstein College of Medicine

Pfizer (United States)

Certara (United States)

Bristol-Myers Squibb (United States)

Robert Croop is an author at Biohaven Pharmaceuticals (United States) specializing in pharmacology, pharmacotherapy, and clinical pharmacology.

ORCID

Publications per year

1995–2025

41

Publications

41

Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine

Richard B. Lipton, Robert Croop, Elyse Stock et al. · New England Journal of Medicine · 2019 · 396 citations · Full text

, , +14

Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial

Robert Croop, Peter J. Goadsby, David Stock et al. · The Lancet · 2019 · 392 citations

, , +12

Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial

Robert Croop, Richard B. Lipton, David Kudrow et al. · The Lancet · 2020 · 351 citations

, , +12

The Safety Profile of Naltrexone in the Treatment of Alcoholism

Robert Croop · Archives of General Psychiatry · 1997 · 214 citations

, , +13

Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial

Richard B. Lipton, Robert Croop, David Stock et al. · The Lancet Neurology · 2023 · 145 citations

, , +14

1–5 of 41